Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 27,716.0 | 21,974.0 | 28,159.0 | 26,607.0 | 35,010.0 | 34,203.0 | 31,628.0 | 33,050.0 |
| Revenue growth | 26.1% | -22.0% | 5.8% | -24.0% | 2.4% | 8.1% | -4.3% | 4.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 2,033.0 | 2,018.0 | 1,837.0 | 1,854.0 | 1,807.0 |
| Gross profit | 27,716.0 | 21,974.0 | 28,159.0 | 24,574.0 | 32,992.0 | 32,366.0 | 29,774.0 | 31,243.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 92.4% | 94.2% | 94.6% | 94.1% | 94.5% |
| Selling, general and administrative | | | | | | | 8,085.0 | |
| Sales and marketing | 9,053.0 | 6,747.0 | 7,125.0 | 6,477.0 | 5,722.0 | 6,249.0 | 3,109.0 | 3,216.0 |
| Research and development | | | | | | | 345.0 | 383.0 |
| General and administrative | 6,240.0 | 5,718.0 | 5,911.0 | 5,250.0 | 5,258.0 | 5,259.0 | | |
| EBITA | 2,986.0 | -3,304.0 | 695.0 | 1,070.0 | 1,526.0 | 3,051.0 | 2,386.0 | 2,647.0 |
| EBITA margin | 10.8% | -15.0% | 2.5% | 4.0% | 4.4% | 8.9% | 7.5% | 8.0% |
| Amortization of intangibles | 57.0 | 54.0 | 49.0 | 212.0 | 207.0 | 194.0 | 183.0 | 174.0 |
| EBIT | 2,929.0 | -3,358.0 | 646.0 | 858.0 | 1,319.0 | 2,857.0 | 2,203.0 | 2,473.0 |
| EBIT margin | 10.6% | -15.3% | 2.3% | 3.2% | 3.8% | 8.4% | 7.0% | 7.5% |
| Pre-tax income | 10,689.0 | 4,296.0 | 8,429.0 | 8,122.0 | 7,425.0 | 8,042.0 | 7,938.0 | 8,991.0 |
| Income taxes | 2,629.0 | 1,161.0 | 1,670.0 | 1,201.0 | 4,677.0 | 2,667.0 | 2,775.0 | 3,106.0 |
| Tax rate | 24.6% | 27.0% | 19.8% | 14.8% | 63.0% | 33.2% | 35.0% | 34.5% |
| Net income | 8,060.0 | 3,135.0 | 6,759.0 | 6,921.0 | 2,748.0 | 5,375.0 | 5,163.0 | 5,885.0 |
| Net margin | 29.1% | 14.3% | 24.0% | 26.0% | 7.8% | 15.7% | 16.3% | 17.8% |
| |
| Diluted EPS | $10.20 | $3.89 | $8.14 | $8.06 | $3.10 | $5.75 | $5.15 | $5.60 |
| Shares outstanding (diluted) | 790.0 | 806.0 | 830.0 | 859.0 | 886.0 | 935.0 | 1,003.0 | 1,051.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|